N/A
Completed N=164
Telehealth-Filter Ventilation ( COMET2P1 )
Source: ClinicalTrials.gov NCT04969783 ↗Enrolled (actual)
164
Serious AEs
0.6%
Results posted
May 2025
Primary outcomePrimary: Change in Total NNAL: 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol [ng/g Creatinine] — 0.97; 1.05 ng/g creatinine
Summary
The goals of this project are to determine the effects of varying degrees of cigarette filter ventilation on biomarkers of toxicant exposure and smoking behavior and on subjective responses to the cigarette.
The primary aim of this study is to examine the effects of unventilated vs ventilated filter cigarettes on urinary biomarkers of toxicant exposure and smoking behavior (e.g., cigarettes per day, intensity of smoking). The secondary objectives are 1) to examine the effects of cigarette filter ventilation on subjective measures such as cigarette dependence and responses to study cigarettes.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Total NNAL: 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol [ng/g Creatinine] |
0.97; 1.05 | — |
| PRIMARY Change in Cigarettes Per Day (CPD) |
-0.39; -0.17 | — |
Eligibility Criteria
Inclusion Criteria
- At least 21 years of age
- Biochemically confirmed regular cigarette smoker
- Daily smoker, 5-30 cigarettes per day.
- Usual brand cigarettes 16-36% ventilation
Exclusion Criteria
- Unstable health
- Unstable medications
- Pregnant or nursing
Data sourced from ClinicalTrials.gov (NCT04969783). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.